| 000 | 01202 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250518070746.0 | ||
| 264 | 0 | _c20191125 | |
| 008 | 201911s 0 0 eng d | ||
| 022 | _a1699-3993 | ||
| 024 | 7 |
_a10.1358/dot.2019.55.10.3030645 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPaton, D M | |
| 245 | 0 | 0 |
_aRisankizumab.rzaa: an interleukin monoclonal antibody antagonist binding to the p19 subunit of human IL-23 cytokine. _h[electronic resource] |
| 260 |
_bDrugs of today (Barcelona, Spain : 1998) _cOct 2019 |
||
| 300 |
_a605-613 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xpharmacology |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xpharmacology |
| 650 | 0 | 4 | _aDrug Approval |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterleukin-23 Subunit p19 _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPsoriasis _xtherapy |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 | _aUnited States Food and Drug Administration |
| 773 | 0 |
_tDrugs of today (Barcelona, Spain : 1998) _gvol. 55 _gno. 10 _gp. 605-613 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1358/dot.2019.55.10.3030645 _zAvailable from publisher's website |
| 999 |
_c30306579 _d30306579 |
||